Here, we combined bioluminescence/fluorescence resonance energy transfer, bioluminescence- and fluorescence-based assays as well as migration experiments, with molecular dynamics simulations and allosteric communication networks to define the structural and functional consequences of this mutation. The A338V variant preserved agonist potency and largely maintained or even enhanced agonist-induced Gi protein activation, likely by inducing different receptor core conformations. On the other hand, it consistently impaired GRK2 and β-arrestin2 recruitment across multiple experimental configurations. Atomistic simulations supported these observations and further suggested that A338V reshapes the conformational ensemble of the C-terminal tail, altering its disorder, compaction, and membrane interactions. In particular, the mutation redistributes lipid interactions of phosphorylation-prone serine and threonine residues within the tail, suggesting disrupted spatial presentation of regulatory motifs required for productive GRK2 and β-arrestin coupling. Importantly, overexpression of GPR183 A338V in differentiated HL-60 cells led to a significant increase in migration of these cells toward the chemoattractant. Together, these results identify the intrinsically disordered C-terminal tail of GPR183 as a determinant of selective transducer coupling and show how a single naturally occurring mutation within a GPCR intrinsically disordered region can alter its conformational ensemble, selectively modulate intracellular protein coupling, and affect receptor-mediated cellular behavior.